Skip to content
Screener

EyePoint, Inc. EYPT Investing Cash Flow

Investing Cash Flow at other companies

Merck & Co. logo
Merck & Co.MRK
-$5.6B-628%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$92.7M+91.5%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$4.66M-141%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$942K-249%
Regenxbio logo
RegenxbioRGNX
$65.93M+147%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$68.89M+116%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Sales and maturities of marketable securities145,000182,725
Proceeds from sale of equity investment1,302
Purchases of property and equipment(2,197)(1,496)
Net cash (used in) provided by investing activities134,15687,861
Cash flows from financing activities:
Proceeds from issuance of stock19,622
Payment of equity issue costs(389)(291)
Net settlement of stock units to satisfy statutory tax withholding(3,482)(1,237)

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s investing cash flow?
EyePoint, Inc. (EYPT) reported investing cash flow of $75.1M in Q2 2026.
How has EyePoint, Inc.'s investing cash flow changed year-over-year?
EyePoint, Inc.'s investing cash flow increased by 55.4% year-over-year, from $48.34M to $75.1M.
What is the long-term trend for EyePoint, Inc.'s investing cash flow?
Over 4 years (2021 to 2025), EyePoint, Inc.'s investing cash flow has grown at a 48.3% compound annual growth rate (CAGR), from -$33.12M to $160.39M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about EyePoint, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude